Galenicum, second Spanish pharmaceutical company in patent applications in 2014

March 11, 2015

The European Patent Office (EPO) has published the ranking of patent applications submitted during the 2014 fiscal year in Europe. The pharmaceutical company Galenicum, with 21 applications, is now in the second company in the sector and the fifth at a national level. This is the result of a significant boost in recent years in the area of Intellectual Property and product development.


EPO Graphics Regional 2014

Source: European Patent Office


Javier Torrejón, Director of Research and Development at Galenicum, expressed his satisfaction with the “significant growth achieved by the company in this area, which has permitted us to increase every year the number of developments and the launch of new products, the company’s driving force”. Torrejón also stated that the company forecasts “submitting some 26 new patent applications” by the close of 2015.

These developments have supported the company’s important international expansion process. The company currently has offices in Spain, Brazil, Peru, Malta and China. As well as these countries, Galenicum has a presence in Latin America by means of distribution agreements in Colombia, Panama and the Dominican Republic. Last year, the company also took its first steps in the Asian market with the signing of distribution agreements in Hong Kong, Malaysia, Singapore and Vietnam, which will set the stage for the introduction of the company into the Asian market.


Increase of 3.1% in the number of applications

According to data presented at the end of February, the number of patent applications submitted to the European Patent Office increased for the fifth consecutive year. During the 2014 fiscal year, a total of 275,000 applications were submitted, representing an increase of 3.1% in relation to the previous year and a new record in the total